For many years the mainstay of treatment for metastatic melanoma, chemotherapy is much
less used today. Although a small minority of patients benefit from cytotoxic agents …

This review examines progress in the treatment of metastatic melanoma seen in the past 5
years. It focuses on the development of targeted therapies and immune checkpoint inhibitors …

Amazing progress in improving survival with metastatic melanoma has been made.
Checkpoint immunotherapy, especially in combinations, has changed the prognosis from …

The 10-year survival rate for patients with metastatic melanoma is less than 10%. Although
surgery and radiation therapy have a role in the treatment of metastatic disease, systemic …

Melanoma is a neoplasm with a rising incidence. Early‐stage melanoma is curable, but
advanced, metastatic melanoma almost uniformly is fatal, and patients with such advanced …

Metastatic melanoma remains a lethal disease with a long-term remission rate of less than
10%. Despite many years of research, there has not been a new drug approved in this …

The incidence of cutaneous melanoma has been rapidly increasing, with an estimate of
47,700 new cases diagnosed in 2000 in the United States. In the early phase of its natural …

The introduction in clinical practice of new drug compounds both targeted therapies anti-
BRAF and checkpoint inhibitors have largely improved our potential to manage advanced …

Abstract Purpose of Review In the preceding decade, the management of metastatic
cutaneous melanoma has been revolutionised with the development of highly effective …

There has been a therapeutic revolution in the treatment of metastatic melanoma over the
past decade. Patients presenting with inoperable disease have several therapeutic options …